Global Penny Stocks With Market Caps Larger Than US$60M

Global markets have recently experienced volatility, with major U.S. stock indexes finishing the week lower amid fluctuating oil prices and shifting economic data. Despite these challenges, certain investment opportunities continue to attract attention, particularly in niche areas like penny stocks. While the term 'penny stocks' may seem outdated, it remains relevant as these typically smaller or newer companies can offer significant growth potential when backed by strong financials.

We're going to check out a few of the best picks from our screener tool.

Tong Ren Tang Technologies (SEHK:1666)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tong Ren Tang Technologies Co. Ltd., along with its subsidiaries, is engaged in the production and distribution of Chinese medicine products in Mainland China and Hong Kong, with a market cap of approximately HK$4.65 billion.

Operations: The company's revenue is primarily generated from its main operations, contributing CN¥4.02 billion, and from Tong Ren Tang Chinese Medicine, which adds CN¥1.39 billion.

Market Cap: HK$4.65B

Tong Ren Tang Technologies Co. Ltd. presents a mixed picture for penny stock investors. The company reported CN¥6.48 billion in sales for 2025, with net income declining to CN¥396.28 million from the previous year, reflecting challenges in profitability and growth, as earnings have decreased by 1% annually over five years and dropped 24.1% last year alone. However, its financial stability is evident through strong asset coverage of both short-term (CN¥10.2 billion) and long-term liabilities (CN¥1.7 billion), more cash than debt, and reliable dividend payments of 5.73%. Despite management's lack of experience, the firm trades at a significant discount to its estimated fair value.

• Navigate through the intricacies of Tong Ren Tang Technologies with our comprehensive balance sheet health report here.
• Examine Tong Ren Tang Technologies' earnings growth report to understand how analysts expect it to perform.

Green Energy Group (SEHK:979)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Green Energy Group Limited is an investment holding company involved in the renewable energy sector across Europe, Malaysia, Singapore, Korea, and the People’s Republic of China with a market cap of HK$508.62 million.

Operations: The company's revenue is primarily derived from Renewable Energy (HK$58.78 million), followed by Waste Construction Materials and Processing Services (HK$4.86 million), and Plastic Recycling/Metal Scrap (HK$1.33 million).

Market Cap: HK$508.62M

Green Energy Group Limited, with a market cap of HK$508.62 million, operates primarily in renewable energy across multiple regions. Despite being unprofitable and having a negative return on equity of -53.53%, the company has managed to reduce its losses by 15.2% annually over the past five years and remains debt-free. Short-term assets (HK$27.2M) comfortably cover both short-term (HK$14.3M) and long-term liabilities (HK$1.5M). Recent board changes include Ms. Chan Corrie Wai Yan joining as an independent non-executive director, bringing over 15 years of compliance experience to strengthen governance amidst high share price volatility.

• Jump into the full analysis health report here for a deeper understanding of Green Energy Group.
• Examine Green Energy Group's past performance report to understand how it has performed in prior years.

Huapont Life SciencesLtd (SZSE:002004)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Huapont Life Sciences Co., Ltd. operates in the fields of medicine, medical care, agrochemicals, new materials, and tourism both in China and internationally with a market cap of approximately CN¥8.98 billion.

Operations: No specific revenue segments have been reported for Huapont Life Sciences Co., Ltd.

Market Cap: CN¥8.98B

Huapont Life Sciences Co., Ltd. shows potential as a penny stock with its market cap of approximately CN¥8.98 billion and recent profitability, although earnings have declined by 30.4% annually over the past five years. The company has a satisfactory net debt to equity ratio of 17.8%, and short-term assets (CN¥12.4 billion) exceed both short-term (CN¥8.9 billion) and long-term liabilities (CN¥3.6 billion). Despite low return on equity at 5.1%, the management team is experienced, averaging 12.4 years in tenure, which may provide stability amidst its volatile earnings history and dividend challenges with a payout not well covered by profits.

• Take a closer look at Huapont Life SciencesLtd's potential here in our financial health report.
• Explore historical data to track Huapont Life SciencesLtd's performance over time in our past results report.

Summing It All Up

• Click through to start exploring the rest of the 3,583 Global Penny Stocks now.
• Ready To Venture Into Other Investment Styles? AI is about to change healthcare. These 132 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.